[{"id":"ed7b8404-0f3f-4d03-b259-8cbdfacd2292","acronym":"KEYNOTE-F62","url":"https://clinicaltrials.gov/study/NCT06108050","created_at":"2023-10-30T16:13:05.018Z","updated_at":"2025-02-25T16:19:13.834Z","phase":"Phase 1","brief_title":"JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT06108050 - KEYNOTE-F62","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" BRAF • MSI","pipe":" | ","alterations":" MSI-H/dMMR • BRAF mutation","tags":["BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • JZP898"],"overall_status":"Recruiting","enrollment":" Enrollment 177","initiation":"Initiation: 11/07/2023","start_date":" 11/07/2023","primary_txt":" Primary completion: 11/30/2027","primary_completion_date":" 11/30/2027","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-02-05"}]